A company that’s developing nutritional supplements tailored to people with heart disease and heart failure has raised more than $1 million in equity.
Dayton, Ohio-area Corceuticals’ funding was sourced from 34 investors, according to a regulatory document.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Corceuticals says its CardiaMin supplement “provides a carefully selected blend of vitamins and minerals while avoiding those which can be harmful or counteract medications commonly used by people with heart disease or heart failure.”
A 30-day supply of the vitamin costs $22.
Corceuticals is a subsidiary of Nephroceuticals, which develops vitamins for people with chronic kidney disease.
A company representative didn’t return a call.
